Washington State University
Trial Pipeline
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
NCT07393672
Developing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery
NCT07052318
Impact of Cannabinoids on Menopause Symptoms
NCT06831916
FAmily Engagement Strategy for Coordinated Specialty Care
NCT06945055
Cognition After OSA Treatment Among Native American People (CATNAP)
NCT06227572
Acute Psychological and Physiological Effects of Cannabigerol
NCT06638996
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
NCT06693960
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
NCT06692933
Virtual Incentive Treatment for Alcohol
NCT06265506
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
NCT06323837
Automated Reinforcement Management Systems, Phase II
NCT06456905
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
NCT06053411
Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints
NCT05846451
Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation
NCT05733442
Family Peer Navigator for Early Psychosis for Black Families
NCT05284721
Indian Transforming Alzheimer's Care Training (INTACT)
NCT06397339
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
NCT05181891
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
NCT05134857
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
NCT04783558
Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering
NCT05924022
Caring Contacts: A Strength-based, Suicide Prevention Trial in 4 Native Communities
NCT02825771
Community-Engaged Options to Facilitate Opioid Reduction
NCT05098158
Naturalistic Monitoring and Treatment of Chronic Insomnia
NCT04013321
Phosphatidylethanol-Based Contingency Management for Housing
NCT04038021
Barley Beta-glucan, Glycemic Control, and Appetite
NCT06146322
Motivational Incentives for Alcohol Abstinence in American Indian and Native Alaskan Adults
NCT02174315
Regional Native American Community Networks Program (RNACNP)
NCT02843217
Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy
NCT00634998
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 34 |
| Phase 2 | 5 |
Therapeutic Areas
What the Pipeline for Washington State University Shows
According to the ClinicalTrials.gov registry, Washington State University is linked to 84 US clinical trials across every stage of research activity. Of those, 74 studies are currently recruiting — about 88% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 8% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Washington State University reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 39 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Washington State University is Alcohol Use Disorder (AUD) with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.